Ypsomed's autoinjector YpsoMate

Promising start-up opts for Ypsomed's user-friendly autoinjector to treat PMDD

YpsoStories

Asarina Pharma has decided to go with our user-friendly two-step autoinjector YpsoMate for its commercial launch of its drug Sepranolone. Sepranolone is the world’s first treatment for pre-menstrual dysphoric disorder (PMDD).

Topics:
Innovation

YpsoDose patch injector in use

Satisfied user study participants

YpsoStories

YpsoDose is a patch injector for large volumes. When developing YpsoDose, we focus on user-friendliness as we do with all our injection systems. The latest user studies have confirmed how easy YpsoDose is to use. 

Topics:
Innovation

Ypsomed autoinjector
Our autoinjector YpsoMate is launched on the market by renowned biotech companies.

YpsoMate's platform approach is paying off

YpsoStories

Several customers have recently launched their autoinjectors based on our YpsoMate platform product technology on the market. Customers value the fast product customisation as well as the individual design possibilities. End users appreciate its user-friendliness.

Topics:
Innovation

Digitisation in diabetes therapy management

Changing patient-doctor relationship

YpsoStories

Digitisation opens the door for new products and new possibilities in the diabetes therapy management. Due to digitisation, patients are gaining knowledge and independence and therefore their demands increase. As a result, the patient-doctor relationship is undergoing change.

Topics:
Innovation

Individualisation in diabetes therapy

YpsoStories

The number of Type 1 diabetics using old insulin pumps without secure communication interfaces to build their own “Closed Loop” system is growing steadily. The so-called “loopers” are thus sending a clear signal to manufacturers and showing what is in demand for insulin pump therapy.

Topics:
Innovation